Last edition
News about "Kite Pharma"
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Kite Pharma | 22/05/2026 | By News Bureau | 428
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Kite Pharma | 29/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy